Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Maverick Therapeutics Inc.
Headquarters: Brisbane, CA, United States of America
Website: N/A
Year Founded: 2016
Status: Acquired
BioCentury | May 25, 2022
Management Tracks
Manner becomes CEO of OraSure
Plus Afeyan to chair Rubius, Chroma adds Golumbeski to board, Maraganore as adviser
BioCentury | Feb 2, 2022
Management Tracks
Roche’s William Pao joins Pfizer as CDO
Plus Clevers succeeds Pao at Roche, new CEO, CFO and other changes at Sosei and updates from Biomea, BeiGene, Cortexyme and more
BioCentury | Jan 10, 2022
Deals
Adaptate takeout is Takeda’s latest move in γδ sector
Build-to-buy deal gives Takeda set of γδ antibodies, paired with existing T cell therapy holdings
BioCentury | Sep 23, 2021
Management Tracks
Alnylam vet Smith joins MPM
Plus: Yi to leave Cerevel, Dicerna, Verastem, MiroBio,
BioCentury | Jun 17, 2021
Management Tracks
Syncona expands C-suite; plus Myriad, Aulos, Cytovia, Elevation and more
Syncona Ltd. (LSE:SYNC) hired Rolf Soderstrom as CFO, Markus John as CMO and head of R&D and Fiona Langton-Smith as chief human resources officer. Soderstrom, who previously served as CFO of BTG
BioCentury | Jun 15, 2021
Management Tracks
Avila joins Atea as SVP of medical affairs; plus Werewolf, Senda, Aurion, Sigilon and more
Viral infections company Atea Pharmaceuticals Inc. (NASDAQ:AVIR) hired Claudio Avila as SVP of medical affairs. Avila joins from Gilead Sciences Inc. (NASDAQ:GILD), where he was executive director of
BioCentury | Mar 16, 2021
Deals
Vaccine vexed; plus assessing Lilly’s Alzheimer’s data & PDUFA preview: a BioCentury podcast
The only thing that’s clear from the latest big Alzheimer’s readout is that the entrenched camps of amyloid believers and doubters will take predictably polarized views. On the latest
BioCentury | Mar 10, 2021
Deals
Maverick takeout adds T cell-engagers to Takeda’s solid tumor toolkit
The acquisition fits squarely in Takeda’s transformation from a small molecule company to one built on multiple modalities.
BioCentury | Nov 20, 2019
Financial News
Werewolf debuts with $56M to develop tumor-activated biologics
BioCentury | Aug 8, 2019
Emerging Company Profile
Akrevia: Masking immunotherapies en route to tumors
Akrevia is getting around immunotherapy toxicity by masking biologics until they reach tumor microenvironment
Items per page:
1 - 10 of 26